A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
← catalyst calendarSponsored by Rigel Pharmaceuticals (industry) · RIGL — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
90estimated
Sites
37
Countries
Australia, Austria, Belarus +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-30 | actual | When the study began enrolling |
| Primary completion | Apr 2024 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2024 | estimated | The whole study's end, after follow-up |
| First posted | 2019-10-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Warm Antibody Autoimmune Hemolytic Anemia
Intervention
- Drug: Fostamatinib disodium — also filed as R935788, Fostamatinib
Primary outcomes
what the primary-completion date above is the date OFAdverse Events
measured 104 weeks
Blood Pressure
measured 104 weeks
Absolute Neutrophil Count (ANC)
measured 104 weeks
Permalink · RIGL's whole pipeline · Catalyst calendar · Every registered study · What changed